Welcome to our dedicated page for Algernon Pharmac news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on Algernon Pharmac stock.
Algernon Pharmaceuticals Inc. (AGNPF) is a clinical-stage biopharmaceutical company advancing innovative therapies for neurological conditions through drug repurposing and clinical research. This news hub provides investors and industry observers with timely updates on the company's scientific progress and corporate developments.
Access comprehensive coverage of AGNPF's press releases, including clinical trial results, regulatory milestones, and strategic partnerships. The curated collection serves as a centralized resource for understanding the company's research initiatives in stroke treatment and neurodegenerative disorders.
Key updates feature developments related to NP-251 (Repirinast) and other pipeline candidates, alongside analysis of trial designs and scientific collaborations. Content is organized to highlight material events while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined access to Algernon Pharmaceuticals' official communications and third-party coverage. Regularly updated to reflect new developments in neuroscience research and biopharmaceutical innovation.
Algernon Pharmaceuticals Inc. has received a Notice of Allowance from the USPTO for its patent application 17/258,402, which pertains to the treatment of Non-Alcoholic Steatohepatitis (NASH) using its lead drug, NP-251 (Repirinast). This significant allowance covers compositions and methods for treating non-alcohol fatty liver disease, supported by data showing Repirinast reduced hepatic fibrosis by 57% and NAFLD scores significantly. The company emphasizes that Repirinast is also a candidate for chronic kidney disease due to its efficacy in reducing fibrosis. In addition, Algernon aims to protect its intellectual property through international patent applications. This is a milestone for Algernon's drug repurposing program, according to CEO Christopher J. Moreau.
Algernon Pharmaceuticals has completed dosing the second cohort in its Phase 1 clinical study of an intravenous DMT formulation, AP-188. The study aims to assess safety, tolerability, and pharmacokinetics of DMT when administered via prolonged infusion. Following safety review committee approval, the final cohort will begin dosing soon. The study plans to include up to 60 volunteers, both experienced and inexperienced with psychedelics. The company is also collaborating with experts to prepare for Phase 2 trials aimed at treating brain injuries. Algernon has patented new formulations of DMT for potential stroke-related applications.
On April 3, 2023, Algernon Pharmaceuticals announced that its subsidiary, Algernon NeuroScience, qualified its Form 1-A offering statement with the SEC for a Tier II Regulation A+ offering. AGN Neuro plans to offer up to 37.5% of its common shares, primarily to fund its Phase 1 DMT study and upcoming Phase 2a studies for stroke and traumatic brain injury. Shares will be priced at USD $1 each, with various bonus share incentives for larger investments. The DMT program is valued at USD $20 million, based on market comparisons. A digital marketing campaign for the offering is expected to launch in early May 2023.
FAQ
What is the current stock price of Algernon Pharmac (AGNPF)?
What is the market cap of Algernon Pharmac (AGNPF)?
